Bleeding Events After Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review

J Am Coll Cardiol. 2023 Feb 21;81(7):684-702. doi: 10.1016/j.jacc.2022.11.050.

Abstract

Transcatheter aortic valve replacement (TAVR) has gained over time a major reduction in procedural complications. Despite this, clinically relevant bleeding still occurs in a non-negligible proportion of patients and adversely affects prognosis. Patients with severe aortic stenosis are at heightened risk for spontaneous bleeding due to advanced age and a high comorbidity burden. Also, procedural factors and antithrombotic management contribute to define individual bleeding susceptibility. Bleeding prevention represents an emerging area for improving patient care. Because of the tight hemorrhagic/ischemic balance, a tailored approach based on individual bleeding-risk profile, such as a less invasive antithrombotic regimen or appropriate diagnostic preprocedural evaluation, should be pursued to avoid bleeding events. This review aims to provide an in-depth overview of bleeding events in the TAVR field, including definitions, timing and the extent of risk, and clinical impact, as well as updates on antithrombotic management and its potential influence on bleeding complications.

Keywords: TAVR; bleeding; transcatheter aortic valve replacement.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aortic Valve / surgery
  • Aortic Valve Stenosis* / drug therapy
  • Aortic Valve Stenosis* / surgery
  • Fibrinolytic Agents / therapeutic use
  • Hemorrhage / drug therapy
  • Hemorrhage / epidemiology
  • Hemorrhage / etiology
  • Humans
  • Risk Factors
  • Transcatheter Aortic Valve Replacement* / adverse effects
  • Treatment Outcome

Substances

  • Fibrinolytic Agents